Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
Johnson & Johnson (NYSE: JNJ) will present at the 7th Annual Wolfe Research Healthcare Conference on Monday, November 17th, 2025. Management will participate in a Fireside Chat at 10:40 a.m. Eastern Time.
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the initiation of its pivotal Phase 2 DAYBreak clinical study. This critical advancement focuses on bexobrutideg (NX-5948), an investigational Bruton's tyrosine kinase (BTK) degrader,
Intuitive Surgical (NASDAQ: ISRG), the global leader in robotic-assisted surgery, announced a robust third quarter for 2025, sending its stock soaring as investors cheered impressive financial results and strong adoption of its latest da Vinci 5 surgical system. The company's report, released on October 21, 2025, showcased significant revenue and
Boston Scientific (NYSE: BSX) has delivered an exceptional third-quarter 2025 earnings report, significantly surpassing analyst expectations and reinforcing its position as a leading innovator in the medical device industry. The strong performance, highlighted by robust sales growth and an upward revision of full-year guidance, has sent a positive signal to
WASHINGTON D.C. – October 21, 2025 – A concerning report from investment giant Vanguard has cast a long shadow over the U.S. labor market, revealing that job growth plummeted to a mere 0.1% for seven of the first nine months of 2025. This alarming deceleration, with September 2025 hitting
The International Monetary Fund (IMF) has issued a stark warning regarding the global economic outlook, projecting a deceleration in growth coupled with an alarming rise in debt risks for developing economies. This pronouncement, a consistent theme across its recent World Economic Outlook (WEO) and Fiscal Monitor reports, paints a challenging
After a decade of significant underperformance, marked by legal battles and strategic drift, industrial conglomerate 3M Company (NYSE: MMM) is now making aggressive moves to reclaim its former glory. MarketMinute predicts that this Dow Jones value stock, which has largely languished with minimal returns relative to the broader market over
The stage is set, and the curtains are about to rise on the Q3 2025 earnings season, a period historically known to inject both volatility and direction into the financial markets. As investors brace for a deluge of corporate financial reports, the overarching sentiment is one of cautious optimism, albeit
October 2025 has proven to be a turbulent month for global financial markets, as the persistent shadow of trade tensions and tariffs, particularly between the United States and China, continues to dictate investor sentiment and market volatility. While the month witnessed a dramatic escalation in rhetoric and retaliatory measures, a
The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened interest is not merely an isolated phenomenon but rather a potent indicator of broader market movements, significantly impacting stock futures and the
The global economy is bracing for a significant deceleration in 2025, a trend intensified by persistent trade tensions and widespread policy uncertainties. At the heart of this growing fragility lies China, the world's second-largest economy, whose third-quarter Gross Domestic Product (GDP) growth figures, expected to be unveiled tomorrow, October 20,
Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets.
Global financial markets are currently navigating a treacherous landscape marked by a pronounced surge in investor risk aversion. As of October 16, 2025, a potent cocktail of persistent geopolitical instability, enduring economic uncertainties, and lingering concerns over banking sector fragility has compelled investors to retreat from riskier assets, fundamentally reshaping
Global financial markets are currently gripped by a palpable sense of unease and heightened volatility as October 2025 unfolds. A complex interplay of escalating geopolitical tensions, persistent economic uncertainties, and burgeoning credit concerns is driving a significant shift in investor sentiment towards caution and risk aversion. This environment is characterized
New York, NY – October 16, 2025 – The Consumer Staples and Healthcare sectors of the S&P 500 are experiencing a notable day of underperformance, largely overshadowed by the precipitous stock plunge of Kenvue (NYSE: KVUE). The consumer health giant, spun off from Johnson & Johnson (NYSE: JNJ), is grappling with a
The Federal Reserve Bank of San Francisco's latest "SF FedViews" publication, released on October 16, 2025, offers a nuanced picture of the U.S. economy, highlighting inconsistent progress on inflation and a discernibly softening labor market. This pivotal report, delivered by Sylvain Leduc, executive vice president and director of research,
New York, NY – October 16, 2025 – Johnson & Johnson (NYSE: JNJ), once considered a stalwart of stability, is currently navigating turbulent waters, finding itself among the market's bottom performers today. The precipitous drop in its stock is directly linked to an escalating barrage of talc-related lawsuits, including a staggering £1 billion
Kenvue (NYSE: KVUE), the consumer health giant spun off from Johnson & Johnson, has found itself at the bottom of today's market performance, with its stock price experiencing a significant decline. As of October 16, 2025, the company's shares are trending down by 10.3% and have marked a year-long decline
